Abivax: four abstracts to be presented on obefazimod

(CercleFinance.com) - Abivax announces the presentation of four scientific abstracts on its lead drug candidate, obefazimod, in moderately to severely active ulcerative colitis (UC) and in a preclinical model of colon cancer.


These new preclinical data demonstrate the impact of obefazimod on tumor reduction in the azoxymethane/sodium salt dextran sulfate mouse model of inflammation-associated cancer," says Medical Director Sheldon Sloan.

Abstracts will be presented at Digestive Disease Week (DDW), May 18-21 in Washington, D.C., giving the biotech company the opportunity to continue its exchanges with the community of experts in this field.

Copyright (c) 2024 CercleFinance.com. All rights reserved.